How Is West Pharmaceutical's Stock Performance Compared to Other Healthcare Stocks?

Company Overview - West Pharmaceutical Services, Inc. (WST) has a market cap of $16.6 billion and specializes in designing, manufacturing, and selling containment and delivery systems for injectable drugs and healthcare products globally [1] - The company operates through two segments: Proprietary Products, which includes stoppers, seals, syringe and cartridge components, and drug containment solutions, and Contract-Manufactured Products, focusing on medical and drug-delivery device design and automated assembly [1] Market Position - As a large-cap stock, West Pharmaceutical is valued at $10 billion or more, fitting perfectly within this classification [2] - The company is headquartered in Exton, Pennsylvania, and primarily serves pharmaceutical, biologic, diagnostic, and medical device companies through a global sales and distribution network [2] Stock Performance - Shares of West Pharmaceutical have decreased 27.9% from their 52-week high of $322.34, and have fallen 13.4% over the past three months, underperforming the State Street Health Care Select Sector SPDR ETF (XLV), which dipped by 1.9% during the same period [3] - Year-to-date, WST stock has declined 15.7%, while XLV has dropped by 2.4% [6] - Over the past 52 weeks, shares of West Pharmaceutical have risen 3.6%, compared to XLV's 5.1% gain [6] - The stock has been trading below its 50-day moving average since mid-January [7] Financial Performance - In Q4 2025, West Pharmaceutical reported net sales of $805 million, reflecting a 7.5% increase, and adjusted EPS of $2.04, up 12.1% [8] - Full-year revenue reached $3.07 billion, up 6.3%, with adjusted EPS of $7.29, an 8% increase [8] - High-Value Product (HVP) Components sales grew by 20.3% to $389.8 million, accounting for 48% of total net sales and demonstrating strong double-digit organic growth [8] Future Outlook - The company issued positive guidance for 2026, projecting net sales between $3.22 billion and $3.28 billion, and adjusted EPS of $7.85 to $8.20 [9] - Despite the positive outlook, the stock fell over 1% on the day of the announcement [9] - In comparison, rival The Cooper Companies, Inc. (COO) has shown a less pronounced decline on a year-to-date basis, with COO stock falling 13.3% [9]